一种用于克服非小细胞肺癌治疗中抗原异质性的多靶向 CAR-T 细胞平台
A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.
这些发现支持采用多靶点CAR-T 策略来应对NSCLC及可能其他实体瘤中的抗原异质性。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:The germline HLA-A02B62 supertype is associated with a PD-L1-positive tumour immune microenvironment and poor prognosis in stage I lung cancer.
The germline HLA-A02B62 supertype is associated with a PD-L1-positive tumour immune microenvironment and poor prognosis in stage I lung cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
HLA-A02B62 超型可作为早期肺癌不良预后的可能指标。然而,鉴于其与 PD-L1 阳性肿瘤微环境的关联,它也可能作为免疫治疗有利的预后因素。
生殖系HLA I类分子超型已被证明与抗PD-1治疗的应答相关。在此,我们研究生殖系HLA-A和HLA-B超型在非小细胞肺癌肿瘤微环境中的意义。
共回顾性收集278例NSCLC患者。采用下一代测序进行HLA基因分型。通过多重免疫组化检测评估TIL(肿瘤浸润淋巴细胞)。评估HLA超型、TIL(肿瘤浸润淋巴细胞)与临床病理特征之间的相关性。
HLA-A03 和 HLA-B62 是占比最高的超型,分别为 69.1% 和 52.2%。HLA-A02 或 HLA-B62,而非 HLA-A03,与更高的 PD-L1 + 肿瘤细胞和基质细胞水平、CD68 + 细胞以及 CD68 + PD-L1 + 细胞相关。同时具有 HLA-A02 和 HLA-B62 超型的患者,其 PD-L1 + 细胞、CD68 + 细胞和 CD8 + 细胞水平显著高于其他超型患者(P = 0.0301,P = 0.0479,P = 0.0192)。这些细胞共同构成了一个热但免疫抑制的肿瘤微环境。因此,同时具有 HLA-A02 和 HLA-B62 超型的患者术后无进展生存期较短(HR = 2.27,P = 0.0373)。
Germline HLA class I molecule supertypes are shown to correlate with response to anti-PD-1 therapy. Here, we investigate the significance of germline HLA-A and HLA-B supertypes in tumour microenvironment of non-small-cell lung cancer.
Totally 278 NSCLC patients were collected retrospectively. HLA genotyping was conducted using next-generation sequencing. The evaluation of tumour-infiltrating lymphocytes was performed by multiplex immunohistochemistry assay. Correlations among HLA supertypes, tumour infiltrating lymphocytes, and clinicopathological characteristics were assessed.
HLA-A03 and HLA-B62 were the supertypes with the highest proportions, at 69.1% and 52.2%, respectively. HLA-A02 or HLA-B62, but not HLA-A03, associated with higher PD-L1 + tumour and stromal cells levels, CD68 + cells, and CD68 + PD-L1 + cells. Patients with both HLA-A02 and HLA-B62 supertypes displayed significantly higher PD-L1 + cells, CD68 + cells, and CD8 + cells levels than patients with other supertypes ( P = 0.0301, P = 0.0479, P = 0.0192). These cells collectively constitute a hot but immunosuppressive tumour microenvironment. Accordingly, patients with both HLA-A02 and HLA-B62 supertypes had short progression-free survival after surgery (HR = 2.27, P = 0.0373).
The HLA-A02B62 supertype could serve as a possible indicator of poor prognosis in early-stage lung cancer. However, it may also act as a favorable prognostic factor for immunotherapy, given its association with a PD-L1-positive tumour microenvironment.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。